QUEST DIAGNOSTICS INC (DGX:NYSE)
$235.02 3.88 (1.6786%)
Analysed QUEST DIAGNOSTICS INC (DGX:NYSE) News Sources
Could Roche and Lilly’s Blood Test Make Alzheimer’s Assessment More Accessible?
05-09-2026
yahoo.com
Quest Diagnostics (DGX) Could Be 30% Below Fair Value After Upgrade And WHOOP Deal
20-08-2026
yahoo.com
Is it the Right Time to Retain DGX Stock in Your Portfolio?
21-08-2026
yahoo.com
Quest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's Disease Pathology
24-08-2026
yahoo.com
Quest Diagnostics to Speak at the Baird 2026 Global Healthcare Conference
25-08-2026
yahoo.com
Quest Diagnostics Stock: Is Wall Street Bullish or Bearish?
25-08-2026
barchart.com
Quest’s Expanded Alzheimer’s and Wellness Testing Push Might Change The Case For Investing In DGX
04-09-2026
yahoo.com
Clinical Laboratory Services Market Size, Share & Trends Analysis - Global Opportunity Analysis & Industry Forecast (2026-2036)
04-09-2026
yahoo.com
Quest Diagnostics CEO Sells 10,000 Shares for $2.4 Million
08-09-2026
fool.com
Apple Health app Users to be Able to Order Labs from Quest Diagnostics
09-09-2026
yahoo.com
What is the current price of QUEST DIAGNOSTICS INC (DGX:NYSE)?
The current price of QUEST DIAGNOSTICS INC (DGX:NYSE) is $235.02.
QUEST DIAGNOSTICS INC (DGX:NYSE) absolute price change since previous trading day?
The absolute price change of QUEST DIAGNOSTICS INC (DGX:NYSE) since the previous trading day is $3.88.
QUEST DIAGNOSTICS INC (DGX:NYSE) percentage price change since previous trading day?
The percentage price change of QUEST DIAGNOSTICS INC (DGX:NYSE) since the previous trading day is 1.6786%.
What is the most recent average sentiment score for QUEST DIAGNOSTICS INC (DGX:NYSE)?
The most recent average sentiment score for QUEST DIAGNOSTICS INC (DGX:NYSE) is 77 out of 100.
What is the most recent average sentiment for QUEST DIAGNOSTICS INC (DGX:NYSE)?
The most recent sentiment for QUEST DIAGNOSTICS INC (DGX:NYSE) is .
SEC-8K** Filing Available For QUEST DIAGNOSTICS INC (DGX:NYSE)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.